Human Monoclonal Antibodies Isolated from Spontaneous Epstein‐Barr Virus–Transformed Tumors of Hu‐SPL‐SCID Mice and Specific for Fusion Protein Display Broad Neutralizing Activity Toward Respiratory Syncytial Virus
Citations Over Time
Abstract
Two human monoclonal antibodies, RF-1 and RF-2, specifically recognize the fusion protein of the human respiratory syncytial virus (RSV). These were isolated from spontaneous tumors in SCID mice reconstituted with human splenocytes and boosted with fusion protein. The tumors consisted of Epstein-Barr virus-transformed human B cells in animals with antigen-specific antibody titers>105. The binding affinity of RF-1 and RF-2 to the fusion protein is 1010 and 109 M-1, respectively. The antibodies bind specifically to a conformational epitope of the fusion protein on RSV-infected HEp-2 cells. Both antibodies display virus-neutralizing properties in vitro at concentrations varying between 8 and 1000 ng/mL. Virus neutralization applies to a broad variety of wild and laboratory-adapted virus strains belonging to both virus types A and B. These antibodies are potential candidates for passive immunotherapy of severe RSV infections.
Related Papers
- → Serological anti-SARS-CoV-2 neutralizing antibodies association to live virus neutralizing test titers in COVID-19 paucisymptomatic/symptomatic patients and vaccinated subjects(2021)26 cited
- → Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients(2022)14 cited
- → Correlation between canine distemper and measles virus neutralizing capacities in human sera(1959)13 cited
- → Antibody titers measured by commercial assays are correlated with neutralizing antibody titers calibrated by international standards(2021)13 cited
- Distribution and persistence of neutralizing antibody titer against human cytomegalovirus in plasma donors in Sichuan Province,China(2012)